Larix laricina, an Antidiabetic Alternative Treatment from the Cree of Northern Quebec Pharmacopoeia, Decreases Glycemia and Improves Insulin Sensitivity In Vivo
Figure 2
Area under the curve (AUC) of cumulative change in body weight (CCBW; (a–c)) and cumulative change in energy intake (CCEI; d–f) in C57BL/6 mice treated with either HFD (DIO), or L. laricina at 125 or 250 mg/kg, which was incorporated in the HFD for 8 weeks in the prevention protocol and for the last 8 of 16 weeks in the treatment protocol. Total AUC for CCBW-versus-time (a) or CCEI-versus-time (d) was calculated and then fractionated into the first and second half of the feeding period corresponding to weeks 0–4 (AUCF1; b or e) and weeks 4–8 (AUCF2; c or f), respectively. All values are mean ± SEM. Number of animals/group for prevention protocol DIO = 11; L. laricina 125 = 13; L. laricina 250 = 13, and for the treatment protocol DIO = 7; L. laricina 125 = 5; L. laricina 250 = 8). *denotes significantly different as compared to DIO group (one way ANOVA; post-hoc analysis Holm-Sidak or Bonferroni-Dunn test; ).
